A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL

Leukemia. 2010 Nov;24(11):1972-5. doi: 10.1038/leu.2010.199. Epub 2010 Sep 16.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Antibodies, Monoclonal, Murine-Derived / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Aspartate Aminotransferases / blood
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • Male
  • Middle Aged
  • Neutropenia / chemically induced
  • Rituximab
  • Thrombocytopenia / chemically induced
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Vidarabine
  • fludarabine